CA Patent

CA2289190A1 — Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain

Assigned to Endo Pharmaceuticals Inc · Expires 1998-11-12 · 28y expired

What this patent protects

The neuropathic pain alleviating effectiveness of an antidepressant is significantly potentiated by administering the antidepressant prior to, with or following the administration of a nontoxic NMDA receptor antagonist.

USPTO Abstract

The neuropathic pain alleviating effectiveness of an antidepressant is significantly potentiated by administering the antidepressant prior to, with or following the administration of a nontoxic NMDA receptor antagonist.

Drugs covered by this patent

Patent Metadata

Patent number
CA2289190A1
Jurisdiction
CA
Classification
Expires
1998-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Endo Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.